Berenberg analyst Harry Gillis raised the firm’s price target on BioNTech (BNTX) to $155 from $150 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE: Promising Clinical Trials and Strong Buy Rating Reinforced by Robert Burns
- BioNTech’s Promising Phase 2 Trial Results for Pumitamig in TNBC Justify Buy Rating
- FDA probe into COVID vaccines includes adults, Bloomberg reports
- FDA to investigate COVID vaccine safety across age groups
- BioNTech and BMS Report Promising Phase 2 Results for TNBC Treatment